Clinical Trials

In the first clinical trial on LIVSTEADY™ for athletes, ten highly trained cyclists ingested either LIVSTEADY™ or Maltodextrin while providing blood and expired gas samples every 15 and 30 min, respectively, before, during, and after exercise. The major outcome variables were glucose, insulin, fatty acids, glycerol, and fat oxidation during and after exercise. There was a rapid increase in blood glucose immediately after the ingestion of Maltodextrin pre- and post-exercise, which was significantly attenuated by LIVSTEADY™.

In a similar manner, serum insulin levels were markedly higher after Maltodextrin compared to LIVSTEADY™. Peak insulin levels were more than 8-fold higher after ingestion of Maltodextrin compared to LIVSTEADY™.

LIVSTEADY™ was associated with greater fat breakdown during exercise and recovery as indicated by significantly increased serum non-esterified fatty acids and glycerol levels. There was also a trend for lower respiratory exchange ratios in the LIVSTEADY™ trial compared to Maltodextrin indicating increased oxidation of fat.

In summary, the findings from this carefully controlled experiment confirmed our belief that LIVSTEADY™ would significantly alter metabolic responses to exercise and promote more efficient utilization of fat while maintaining blood glucose levels.